Page last updated: 2024-08-21

indazoles and Chemotherapy-Induced Febrile Neutropenia

indazoles has been researched along with Chemotherapy-Induced Febrile Neutropenia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Bauer, S; Chemnitz, JM; Crysandt, M; Egerer, G; Grünwald, V; Ivanyi, P; Karch, A; Kasper, B; Kopp, HG; Kunitz, A; Lindner, LH; Liu, X; Richter, S; Schöffski, P; Schuler, M; Steffen, B; Stein, A; Zimmermann, S	1
Carlson, DM; Horai, T; Horiike, A; Horinouchi, H; Kaneda, H; McKee, MD; Nakagawa, K; Nishio, M; Nokihara, H; Ohyanagi, F; Okabe, T; Tamura, T; Terashima, M; Xiong, H; Yamamoto, N	1

Trials

2 trial(s) available for indazoles and Chemotherapy-Induced Febrile Neutropenia

Article	Year
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 10-20, Volume: 38, Issue:30 Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Chemotherapy-Induced Febrile Neutropenia; Doxorubicin; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neutropenia; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides	2020
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden	2014

Article

Year

Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 10-20, Volume: 38, Issue:30

Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Chemotherapy-Induced Febrile Neutropenia; Doxorubicin; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neutropenia; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides

2020

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden

2014